David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Welcome and Introduction to Vi3C

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Nov

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Welcome and Introduction to Vi3C

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Active Surveillance With Metformin vs Placebo in Low-Risk Prostate Cancer

Izalontamab Brengitecan in Recurrent or Metastatic Nasopharyngeal Carcinoma

FDA Approves Epcoritamab for Two Follicular Lymphoma Indications

Dexrazoxane Use and Cardiovascular Health-Care Utilization in Children With Acute Myeloid Leukemia

Quality Improvement Program Cuts Missed Radiation Appointments by 40 Percent